ELND006   Click here for help

GtoPdb Ligand ID: 7337

Compound class: Synthetic organic
Comment: ELND006 is a novel γ-secretase inhibitor by Elan Corporation that was in the clinic as a potential treatment for Alzheimer's disease (AD). The clinical trial was halted in October 2010 due to liver side effects that are thought to be unrelated to the mechanism of action [1]
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 74.44
Molecular weight 455.07
XLogP 5.97
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES Fc1cc2c3[nH]ncc3C(N(c2cc1F)S(=O)(=O)c1ccc(cc1)C(F)(F)F)C1CC1
Isomeric SMILES Fc1cc2c3[nH]ncc3[C@H](N(c2cc1F)S(=O)(=O)c1ccc(cc1)C(F)(F)F)C1CC1
InChI InChI=1S/C20H14F5N3O2S/c21-15-7-13-17(8-16(15)22)28(19(10-1-2-10)14-9-26-27-18(13)14)31(29,30)12-5-3-11(4-6-12)20(23,24)25/h3-10,19H,1-2H2,(H,26,27)/t19-/m1/s1
1. Hopkins CR. (2011)
ACS chemical neuroscience molecule spotlight on ELND006: another γ-secretase inhibitor fails in the clinic.
ACS Chem Neurosci, 2 (6): 279-80. [PMID:22778871]
2. Probst G, Aubele DL, Bowers S, Dressen D, Garofalo AW, Hom RK, Konradi AW, Marugg JL, Mattson MN, Neitzel ML et al.. (2013)
Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007): metabolically stable γ-secretase Inhibitors that selectively inhibit the production of amyloid-β over Notch.
J Med Chem, 56 (13): 5261-74. [PMID:23713656]